List of Tecfidera drug patents

Tecfidera is owned by Biogen Inc.

Tecfidera contains Dimethyl Fumarate.

Tecfidera has a total of 9 drug patents out of which 0 drug patents have expired.

Tecfidera was authorised for market use on 27 March, 2013.

Tecfidera is available in capsule, delayed release;oral dosage forms.

Tecfidera can be used as method of treating multiple sclerosis, method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine.

The generics of Tecfidera are possible to be released after 16 November, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399514 BIOGEN INC Treatment for multiple sclerosis
Feb, 2028

(5 years from now)

US10994003 BIOGEN INC Dimethyl fumarate and vaccination regimens
Mar, 2035

(12 years from now)

US10555993 BIOGEN INC Dimethyl fumarate and vaccination regimens
Mar, 2035

(12 years from now)

US10391160 BIOGEN INC Dimethyl fumarate and vaccination regimens
Mar, 2035

(12 years from now)

US11007167 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

US11246850 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

US10959972 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

US11129806 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

US11007166 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
M Feb 5, 2023

Drugs and Companies using DIMETHYL FUMARATE ingredient

Market Authorisation Date: 27 March, 2013

Treatment: Method of treating multiple sclerosis; Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of TECFIDERA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic